Cycle Pharma remains interested in acquiring Vanda Pharmaceuticals even after one of Vanda's drugs failed to receive regulatory approval. Cycle Pharma has maintained its takeover offer, but Vanda has confirmed the receipt of an unsolicited, economically identical, non-binding proposal from Cycle Group. Vanda's board has determined that the latest proposal is not in the best interests of the company or its stockholders.